1) Results released from the Phase 3 CLEAR Trial found that lenvatinib combined with EITHER of these two drugs demonstrated significant benefits over sunitinib in patients with advanced RCC:
a) pembrolizumab or atezolizumab
b) pembrolizumab or everolimus
c) pembrolizumab or nivolumab
d) pembrolizumab or axitinib
The Answer is B. The lenvatinib plus pembrolizumab and the lenvatinib plus everolimus group demonstrated a significantly longer progression-free survival than the sunitinib group (lenvatinib plus pembrolizumab: 23.9 months, 95% CI 20.8 – 27.7; lenvatinib plus everolimus: 14.7 months; 95% CI CI 11.1 – 16.7; sunitinib: 9.2 months; 95% CI 6.0 – 11.0). The overall survival analysis at 24 months follow-up favored the lenvatinib plus pembrolizumab group (79.2% survival) over the sunitinib group (70.4% survival, HR 0.66, 95% CI 0.49-0.88, P=0.005).
From Physician’s Weekly feature, New Combination to Treat RCC Provides “CLEAR” Results in Phase 3 Trial
2) Extended follow-up results from Phase III JAVELIN (avelumab + axitinib vs sunitinib) in elderly patients with advanced RCC demonstrated a reduction in efficacy and safety profile for patients over the age of 75 years.
The Answer is B. A + Ax demonstrated favorable efficacy across age groups as well as a consistent safety profile, including patients aged ≥75. OS was still immature; follow-up for the final analysis is ongoing.
From Physician’s Weekly feature, Follow-Up on Phase III JAVELIN Renal Trial: A+Ax vs S
3) Results from the NAXIVA trial evaluating the effect of axitinib on venous tumor thrombus in RCC found what response rate, necessitating less invasive surgery?
The Answer is C. The researchers concluded the use of axitinib prior to surgery for RCC could decrease VTT extension and thus enable a less invasive surgical approach, which reduce the morbidity and mortality currently associated with extirpative surgery for VTT in RCC, as well as to increase survival time.
From Physician’s Weekly feature, Hope for Improving Renal Cell Cancer Surgical Outcomes
4) Given that there is no optimal therapy for metastatic pRCC, a study comparing standard, sunitinib, to putative MET kinase inhibitors found that what treatment achieved significant prolongation of PFS?
The Answer is D. In this multi-arm randomized trial, only cabozantinib resulted in a statistically significant and clinically meaningful prolongation of PFS in pRCC patients compared to sunitinib. These data support cabozantinib as a reference standard for eligible patients with metastatic pRCC.
From Physician’s Weekly feature, MET Kinase Inhibitors Vs Sunitinib for pRCC
Leave a Reply